• Brain+ to build relationships with Germany's largest caregiver organizations which are also potential future key customers
• Selection of Brain+ for the alliance by the Foreign Ministry validates the potential of Brain+'s Digital Therapeutis (DTx) products and gives credibility with German caregiver organizations

Germany is the largest European market. With approximately 15,000 elderly care homes and 3.7 million people in need of care, Germany is the largest European market for Brain+. The elderly care homes both take care of people with dementia, of whom there are over 1.5 million people in Germany and of healthy elderlies who are at higher risk of Alzheimer's disease and dementia due to their age. The market potential for digital Alzheimer's and dementia therapies in Germany alone is roughly €500 million, by the company's estimate correlated with analyst forecasts for digital therapeutics.

Germany is a global frontrunner. Germany offers a great and immediate market opportunity to Brain+ because Germany is showing the way in the promotion and adoption of digital therapies and has established a national centralized reimbursement process for digital therapies and care technologies to help drive adoption. Brain+ is working with Rox Health, the subsidiary of Roche pharma, to bring its dementia products through this process. The partnership with Rox Health was announced in December, in which context it was also informed that the collaboration would advance the launch of Brain+'s first product with two years to 2023 from 2025 (expected at the time of the IPO).The Danish-German Care Alliance is expected to give additional momentum to the launch of Brain+' first dementia product on the German market. In a global context, The German market is a `reference' market, and if Brain+ can succeed here it creates a strong base for global expansion.

Strong local presence and adaptation: As part of the Danish-German Care Alliance, Brain+ will get first-hand experience and education about the German care home market directly as well as expertise in the procurement process and market information on care needs and trends. In addition to this, the Danish foreign ministry staff in Germany will be educated on Brain+'s Cognitive Stimulation Therapy dementia product so they can act as Brain+ `representatives' when meeting with relevant care homes and customers in Germany.

Beth Wolff, Chief Commercial Officer, Brain+: "We look forward to initiating the cooperation with our new network at Danish-German Care Alliance. I think this is a perfect `on the ground' commercial activity, which goes hand in hand with the strategic work we are doing with Biogen's Neurotech-prize program and the current regulatory, clinical and reimbursement work we are doing with RoX Health. More broadly speaking, I am pleased that we are beginning to build relationships with relevant German dementia care providers and their organizations".

To learn more, see this short video interview with Brain+ CEO and Chief Commercial Officer, here. https://vimeo.com/687932004

About BRAIN+ [BRAINP]

PROBLEM: Dementia is a terrible condition, crippling a person's independence and putting a heavy burden also on the family. With an aging population, dementia is threatening to overwhelm the health care systems of the world. New treatments and therapies are greatly needed.

VISION: Making effective dementia treatments available to everyone, as digital medicine.

MISSION: To restore patients' independence and quality of life by treating and detecting cognitive decline in Alzheimer's disease and dementia.

SOLUTION: Digitizing best-in-class non-drug dementia therapies and enhancing them with cutting edge digital technologies, together with the world's leading experts, making them available on computers and smart phones in people's homes or at the clinic. A therapy here, simply means a person having to actively do something, interacting with a software program or another person, which is stimulating to the brain, or which results in changes in behavior that brings measurable health benefits. Such therapies can be used on their own or be combined with traditional drug treatments.

OUR DNA: We operate like a digital biotech company; our technologies and products are being rigorously tested, scientifically and clinically validated, regulated as medical products, and reimbursed and paid for by the state or health insurances.

POTENTIAL: The global costs of dementia will be $2 trillion in 2030 (or equal to 2/3rds of the entire health care spend of the USA), the estimated market potential which our digital products could address will be $24 billion and growing rapidly, and our target in 2030 is revenue in the hundreds of millions $ based on licensing deals with strategic commercial partners, and we aim to close a first large multi-million $-deal in 2025.

TEAM & TECH: We have built our knowledge base, know-how and network of global expert collaborators, over 10 years, and our technology portfolio is the results of R&D investments of over €10 million, which puts us in a unique position to become a global market leader in digital therapeutic solutions for dementia and Alzheimer's. We have a team with the deep and necessary expertise to succeed, including our Director of Science & Innovation from Coloplast, our CTO from Lundbeck, our Chief Commercial from Novartis, and our CFO from GN Hearing.